CONFERENCE UPDATE: AAN 2023

Oral ozanimod treatment demonstrates long-term efficacy in improving CPS of RMS patients: The phase 3 SUNBEAM and DAYBREAK open-label extension studies

NEUROLOGY
16 Jun 2023

Get access to our exclusive articles.
Related Articles

Sustained efficacy and safety of ozanimod demonstrated in the DAYBREAK open-label extension study

Relapsing multiple sclerosis (RMS) is the most common phenotype of multiple sclerosis (MS) characterized by episodes of transient exacerbations of neurological disability.1 Ozanimod is a sphingosine 1-phosphate (S1P) receptor 1 and 5 modulator.2 Its effect on RMS have been studied in multiple clinic
NEUROLOGY
09 May 2024